Results 41 to 50 of about 15,940 (198)

Attenuated Bacteria‐Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies

Advanced Science, EarlyView.
This review comprehensively overviews attenuated bacteria‐based tumor therapy, highlighting key methodologies and recent progress. It examines strategies for enhancing safety, stabilizing efficacy, optimizing manufacturing, and navigating regulatory pathways.
Yucheng Liu, Junhong Yao, Jiaxin Deng, Minjie Zhou, Kaiyue Shen, Shishuo Sun, Xiaoge Gao, Qing Zhang, Haiheng Xu   +8 more
wiley   +1 more source

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy

Advanced Science, EarlyView.
This study identifies Lactobacillus rhamnosus as an intrinsic oncolytic agent that triggers tumor metabolic collapse via calcium‐dependent ROS bursts. By chemically anchoring collagen‐targeting “molecular pili” to the bacterial surface, the engineered non‐transgenic probiotic (LR@MP) achieves targeted colonization and potent solid tumor suppression ...
Haodong Ge, Chengsheng Ding, Xiao Yang, Si Gao, Changjie Yang, Yuchen Hou, Hongye Wang, Linke Bian, Hao Zhong, Yifan Qu, Luyang Zhang, Junjun Ma, Zhengwei Cai, Wenguo Cui, Minhua Zheng   +14 more
wiley   +1 more source

Fusogenic Viruses in Oncolytic Immunotherapy [PDF]

Cancers, 2018
Oncolytic viruses are under intense development and have earned their place among the novel class of cancer immunotherapeutics that are changing the face of cancer therapy. Their ability to specifically infect and efficiently kill tumor cells, while breaking immune tolerance and mediating immune responses directed against the tumor, make oncolytic ...
Teresa Krabbe, Jennifer Altomonte
openaire   +3 more sources

Current strategies in engaging oncolytic viruses with antitumor immunity

Molecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni, Divya Ravirala, Shaun Xiaoliu Zhang   +2 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

Viruses, 2015
Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor growth. These viruses, through their natural ability or through genetic modifications, can selectively replicate within tumor cells and induce cell death ...
Karishma R. Rajani, Richard G. Vile
doaj   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Advanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu, Ling Peng, Lu Lu, Huiyi Feng, Yan Zhong, Guisen Tan, Zhicheng Zhang, Liqin Huang, Chao Su, Ying Xue, Shuo Song, Wenxia Fan, Wei Wang, Fan Zou   +24 more
wiley   +1 more source

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

Micromanaging oncolytic viruses [PDF]

Science-Business eXchange, 2008
Two research teams have applied a microRNA-based strategy for restricting the replication of oncolytic viruses to their target tumors. The approach seeks to avoid attenuation of the viral genome, a currently used technique that has so far avoided off-target effects but also limited the effectiveness of these agents as cancer therapies.
openaire   +1 more source

The combination therapy of oncolytic virotherapy

Frontiers in Pharmacology
Introduction: Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction.
Yue Wang, Mengying Zhu, Mengying Zhu, Huanyu Chi, Huanyu Chi, Yang Liu, Guilin Yu   +6 more
doaj   +1 more source